Weight loss drugs 2026: which ones are actually approved in the U.S.?

If you search weight loss drugs 2026, the U.S. list looks bigger than it really is. Scroll past the affiliate junk and the recycled Reddit posts, and as of April 2026 the on-label names that matter are Zepbound, Wegovy, Foundayo, Saxenda, Qsymia, Contrave, Xenical, Alli, Imcivree, and a handful of older short-term stimulants.

The catch is that FDA-approved, actively marketed, covered by insurance, and commonly searched are four different buckets. A patient may ask for Mounjaro, mean Zepbound, get quoted a Wegovy savings offer, and still leave without a covered fill, somewhere between hopeful and defeated. That's the whole problem with obesity-drug content in the U.S. right now.

On the approval side, the newest big change is Foundayo. FDA approved it on April 1, 2026, and the agency's own 2026 approvals page says the use is chronic weight management in adults with obesity or adults with overweight plus at least one weight-related comorbid condition.

"reduce excess body weight and maintain weight reduction long term" — FDA on Foundayo, April 1, 2026

That one line is the cleanest starting point. It tells you the April 2026 market isn't a single GLP-1 story anymore. It's a mix of injections, pills, prescription-only options, one OTC product, and a few older stimulant drugs that never left the shelf.

The U.S. list as of April 2026

That table is the easiest way to see why people get lost. The approved list isn't huge. The search traffic around it is.

Approved is not the same as marketed or covered

In a real U.S. clinic, the first obesity-brand names you usually hear are Zepbound, Wegovy, and Foundayo. Not because the older drugs vanished — because those three have the loudest official brand funnels, the most visible manufacturer pages, and the clearest direct-to-patient messaging.

Zepbound is still the tirzepatide brand people associate with the biggest weight-loss numbers. Lilly's official material cites 72-week average weight loss of 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% with placebo in adults without diabetes.

Wegovy is the semaglutide name the U.S. market already knows. The classic 2.4 mg injection data still hang around 15% average body-weight reduction over 68 weeks in the familiar STEP trials. In 2026, the family is bigger than that: there is a once-daily tablet, FDA approved the 7.2 mg Wegovy HD injection on March 19, 2026, and the injectable label also now reaches noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults.

Foundayo is the new one. Lilly's official U.S. pages say adults without diabetes lost about 25 lb, or 11.1%, over 72 weeks at the 17.2 mg dose, and adults with type 2 diabetes lost 21.2 lb, or 9.6%, at the same dose in the diabetes cohort.

The molecule isn't the whole story. Route, dose, label language, and insurance all change the real-world outcome.

If you want the brand-level comparison rabbit hole, this Zepbound vs. Mounjaro explainer and this oral Wegovy comparison are the cleaner side reads.

Search term vs. label name

This table is an editorial read of what U.S. patients keep typing, not an FDA statistic. It's an inference from search-query behavior, and it's exactly where a lot of bad pharmacy advice starts.

The same thing happens over and over: the molecule name is right, but the brand name is wrong for the label the patient needs. You can hear the small pharmacy-counter sigh from the next aisle.

"Mounjaro is not a weight loss drug." — Lilly's Mounjaro FAQ

That sentence is blunt for a reason. It saves people from three days in the wrong part of the internet.

Zepbound, Wegovy, and Foundayo

If you're trying to understand the 2026 obesity market in the U.S., these three names do most of the heavy lifting.

Zepbound is still the cleanest answer if the question is "What is the current tirzepatide obesity brand in the U.S.?" Lilly's public obesity data keep it at the top of the conversation, and the company's site now shows self-pay access paths that make the cash side easy to see.

Wegovy is still the semaglutide brand most U.S. readers recognize first. The injection side is still the familiar obesity story, but by April 2026 the label is wider than that: adults can use a once-daily tablet for weight reduction or cardiovascular risk reduction, the injection has a higher-dose 7.2 mg option, and the injectable brand also carries a noncirrhotic MASH indication. The pill is adult-only, and the routine is strict: take it once daily on an empty stomach with up to 4 oz of water, then wait at least 30 minutes before food, other drinks, or oral medicines.

Foundayo matters for a different reason. It gives no-injection patients a true on-label oral obesity option that Lilly says can be taken any time of day, without food or water restrictions. On April 9, 2026, Lilly said the drug was already available in the U.S. through LillyDirect, telehealth providers, and expanding retail-pharmacy distribution. If you want the full launch-specific version, the Foundayo explainer has the longer read.

The older names that still matter

The GLP-1 headlines are loud, but the older obesity drugs did not disappear just because a new class got attention.

Saxenda is still on-label liraglutide. That matters when a clinician wants a daily GLP-1 but the weekly brands do not fit the plan. Novo's U.S. labeling still covers adults with obesity, adults with overweight plus weight-related conditions, and adolescents age 12 to 17 with obesity. The pediatric threshold gets concrete fast: the adolescent group has to weigh more than 132 lb (60 kg).

Qsymia is still the phentermine/topiramate ER option. It isn't a GLP-1, and that is the point. Some patients do better with a different mechanism, a different side-effect profile, and a different price structure. The label also reaches pediatric obesity care, which is why it keeps showing up in the background even when the weekly injections dominate the news cycle.

Contrave stays in the room too — it isn't a GLP-1, and it isn't a Novo or Lilly drug. Contrave is naltrexone/bupropion ER, and the official site still frames it as chronic weight management for adults with obesity or overweight plus a weight-related medical problem. The label has real numbers attached: the company's materials cite 56-week trial weight loss ranging from 3.7% to 8.1%, versus 1.3% to 4.9% with placebo.

Xenical and Alli are the orlistat branch of the market. Xenical is the 120 mg prescription version. Alli is the 60 mg OTC version. That 120 mg versus 60 mg split is simple, but it's exactly the kind of detail that gets lost when people only remember the brand names. In real U.S. pharmacy traffic, some patients will see generic orlistat 120 mg more often than the Xenical brand name, which is another reason brand-based search can mislead them.

If your question is "Which older drug still makes sense if I don't want a GLP-1?" the honest answer is that this section of the market still exists for a reason. It just doesn't own the search bar anymore.

Imcivree and the short-term stimulants

Imcivree deserves its own lane. It's real obesity medicine, but it is not the mainstream clinic weight-loss conversation most people are having.

Its label now covers two distinct subgroups: acquired hypothalamic obesity in people age 4 and older, plus obesity due to Bardet-Biedl syndrome or certain POMC, PCSK1, or LEPR deficiencies in adults and children age 2 and older. That is specialty obesity medicine, not generic weight-loss prescribing.

The older short-term stimulants are still FDA-approved too. Phentermine's DailyMed label says it is a short-term, "a few weeks" adjunct for patients with BMI 30+, or BMI 27+ with risk factors. Phendimetrazine still carries a short-term obesity label as well. Diethylpropion and benzphetamine sit in the same older sympathomimetic lane. In practice, these are usually generic-fill conversations, not glossy brand-page conversations, which is why they stay medically relevant even when they stop showing up in mainstream obesity marketing.

That is why the market feels split in two. The weekly injection and daily pill story gets the headlines. The older stimulant story still exists for the patients who do not fit the newer lane, or whose access and side-effect profile point somewhere else.

Rx, OTC, and compounding

Only one mainstream obesity medication here is truly OTC: Alli, the 60 mg orlistat product.

Everything else in this post is prescription-only. Some are newer branded products with official manufacturer support. Some are older labels that still have a place in the market. None of that changes the fact that compounded semaglutide or tirzepatide is not the same thing as an FDA-approved product.

FDA has been unambiguous about the risk side of the gray market: dosing errors, counterfeit or fraudulent compounded GLP-1 products, poor shipping and temperature control, and salt forms that don't have a lawful basis for compounding. The approval status is the easy part. The pharmacy-path question is what people keep getting wrong.

If the listing doesn't map to an FDA-approved label, a real brand page, or a legitimate dispensing path, treat it as a different risk category.

Sold does not mean covered

This is where the U.S. system gets annoying fast. A drug can be FDA-approved, widely prescribed, and still be hard to fill at a price that feels sane.

Lilly and Novo both now use official patient pages to show public pricing lanes. Zepbound's self-pay path is public. Foundayo's dose-based price ladder is public. Wegovy's official page now shows separate pill and pen offers. The details change more often than people expect, which is why screenshots age badly.

As of April 2026, Zepbound's official savings page shows regular self-pay pricing of $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for 10 mg, 12.5 mg, and 15 mg, plus a $449 purchase offer on 7.5 mg through 15 mg when the refill-timing rules are met. Foundayo's official savings page shows regular pricing of $149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 for 14.5 mg and 17.2 mg, plus a $299 purchase offer on the two highest doses. Novo's official Wegovy page shows a $149 self-pay pill lane, a commercially insured offer as low as $25, and a separate pen intro offer that was explicitly time-limited and had already shifted during 2026.

That does not mean those are your actual out-of-pocket numbers. It means the brand is willing to put a current public lane on the table. Coverage still depends on the plan, the diagnosis, and the paperwork.

A public cash price is not the same thing as a filled prescription.

The manufacturer terms also make one split explicit: the headline $25 offers are framed around eligible commercially insured patients, and Lilly excludes government-program beneficiaries from those cards. Prior authorization, deductible timing, step therapy, and plan exclusions still decide what people actually pick up at the pharmacy counter.

CMS makes the Medicare split just as clear. In the CY 2026 final rule, CMS did not finalize broader Part D coverage of anti-obesity medications. Under current policy, Part D still covers these drugs when they are being used for another medically accepted indication rather than for weight management alone. CMS's Medicare GLP-1 Bridge FAQs use two concrete examples that matter in clinic: Wegovy for cardiovascular-risk reduction and Zepbound for moderate-to-severe OSA sit in a different Medicare lane than plain obesity treatment.

The practical move is boring and effective: price the exact brand first, not the molecule in the abstract. Zepbound, Wegovy, and Foundayo have very different cash and coverage stories even though they live in the same obesity conversation.

What to ask at the visit

You don't need a long speech. You need a short list that keeps the brand, diagnosis, and access lane lined up.

• What is the main diagnosis on the chart: obesity, obesity plus a comorbidity, obesity plus OSA, or type 2 diabetes?
• Which brand fits that diagnosis: Zepbound, Wegovy, Foundayo, Saxenda, Qsymia, Contrave, Xenical, Alli, or Imcivree?
• Am I looking at a weekly shot, a daily shot, a daily pill, or an older oral option?
• If I want an oral option, is it Foundayo or the Wegovy tablet, and what does the label require?
• What diagnosis code and indication are you actually sending on the prior auth?
• What will my plan ask for: BMI history, prior weight attempts, a prior auth form, or a letter of medical necessity?
• If I have Medicare, is this being submitted for obesity alone or for a separately coverable indication like cardiovascular-risk reduction or OSA?
• If I'm paying cash, which official page should we price first?
• If I have diabetes too, which brand name should lead the prescription?
• If nausea, constipation, or dehydration show up, what is the plan before the dose goes up again?
• If I stop the drug in a year — deliberately or because of cost — what does the regain data look like, and what's the plan to slow it down?

If the answer isn't clear in the room, it won't be clearer at the pharmacy. The counter at 5:55 p.m. on a Friday is not where this gets figured out.

Sources

• FDA novel drug approvals for 2026
• FDA approval announcement for Foundayo
• FDA approval announcement for higher-dose Wegovy
• Wegovy prescribing information
• Zepbound official patient page
• Zepbound prescribing information on DailyMed
• Zepbound savings page
• Mounjaro FAQ
• Wegovy official patient page
• Wegovy official cost and coverage page
• Foundayo official patient page
• Lilly announcement that Foundayo is now available in the U.S.
• Foundayo coverage and savings page
• DailyMed Saxenda prescribing information
• DailyMed Qsymia prescribing information
• DailyMed Contrave prescribing information
• FDA orlistat information for Alli and Xenical
• DailyMed Imcivree prescribing information
• FDA concerns with unapproved GLP-1 drugs used for weight loss
• DailyMed phentermine label
• CMS CY 2026 Medicare Advantage and Part D final rule fact sheet
• CMS Medicare GLP-1 Bridge FAQ

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app